CLINICAL_TRIALS
trial_result
· 2021-12-16
Clinical Trial Update: A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression [Phase 3]
Summary
Phase 3 study evaluating SAGE-217 (zuranolone) in participants with severe postpartum depression has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Postpartum Depression | Phase 3 | Status: COMPLETED | Results posted: 2021-12-16